In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Alterations in cardiac autonomic control in severe idiopathic pulmonary arterial hypertension and its correlation to exercise capacity.

Session Poster Session 7

Speaker Eftihia Simeonidou

Congress : ESC Congress 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Poster Session
  • FP Number : P6339

Authors : E Simeonidou (Athens,GR), H Triantafyllidi (Athens,GR), C Varounis (Athens,GR), K Ntai (Athens,GR), A Voumvourakis (Athens,GR), O Apostolopoulou (Athens,GR), A Anthi (Athens,GR), S Orphanos (Athens,GR), H Tsagaris (Athens,GR), A Armaganidis (Athens,GR), J Lekakis (Athens,GR)

E. Simeonidou1 , H. Triantafyllidi1 , C. Varounis1 , K. Ntai1 , A. Voumvourakis1 , O. Apostolopoulou2 , A. Anthi2 , S. Orphanos2 , H. Tsagaris2 , A. Armaganidis2 , J. Lekakis1 , 1Attikon University Hospital, 2nd University Cardiology Dept - Athens - Greece , 2Attikon University Hospital, PAH Dept, 2nd University Intensive Care Dept - Athens - Greece ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1327-1328

Purpose: Idiopathic pulmonary arterial hypertension (IPAH) is a rapidly progressive disease leading to right heart failure and death. It is already known that in pts with PAH there is an alteration in cardiac autonomic nervous activity. Heart rate turbulence (HRT) is considered a prognostic marker of proarrhythmia and sudden cardiac death, unmasking abnormal transient alterations in cardiac autonomic control. Aim of the study was to examine HRT in patients with severe idiopathic PAH (IPAH) and its relation to exercise capacity.

Methods: The study population consisted of 46 pts, (32 ♀ and 14 ♂), mean age 50±9 years, Group A 20 pts: NYHA III, III–IV diagnosed as severe IPAH and Group B 26 pts: NYHA II, II–III diagnosed as moderately severe IPAH. All pts underwent cardiopulmonary exercise capacity (CPET) assessment and 24h Holter monitoring HRT analysis with calculation of 2 parameters, turbulence onset (TO) and turbulence slope (TS). Abnormal values: TO>0, TS<2.5msec/RR. Pts were defined as HRT (+) when TO or/and TS were abnormal and as HRT (−) when both TO and TS were normal or when HRT could not be calculated because of none or too few suitable PVCs.

Results: Abnormal HRT was found in 12 out of 20 pts (n=12, 60%) in group A and in none out of 26 (n=0, 0%) in group B (p=0,001). There was a tendency to greater TS mean values (±SD) in group B than in group A (6,55±7,5 vs 2,1±1,9 p=0.066). Significant positive correlation was found between TS and maximum oxygen uptake (VO2 max) (r=0,64, p=0,04). The correlation remained significant after adjustment for age and sex [β (SE)=0,0039 (0,001), p=0,028] and was independent of whether the patient was in A or B group [β (SE)=0, 0043 (0,001), p=0,033].

Conclusion: Our study population pts suffering of severe IPAH presented with cardiac autonomic system impairment, demonstrated mainly as abnormal TS in HRT. Interestingly a significant positive correlation was revealed between TS and physical capacity expressed as maximum oxygen consumption in CPET.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are